Paediatric Mycosis Fungoides: Clinical Variants, Treatment Modalities and Response to Therapy.


Journal

Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310

Informations de publication

Date de publication:
14 Jul 2023
Historique:
received: 03 01 2023
accepted: 28 03 2023
medline: 17 7 2023
pubmed: 14 7 2023
entrez: 14 7 2023
Statut: epublish

Résumé

Mycosis fungoides is a rare cutaneous lymphoma in the paediatric population. The aim of this study was to examine the epidemiological, clinical, and histological characteristics, as well as the treatment modalities and response to therapy of paediatric patients with mycosis fungoides. This retrospective cohort study reviewed the records of 37 paediatric patients treated at Rambam Medical Center, Israel, between 2013 and 2021. Extracted data included epidemiology, clinical presentation, histological reports, infiltrate clonality status, treatment modalities and response to therapy. The mean follow-up period was 60 months. All patients were diagnosed with stage IA or IB disease. Folliculotropic mycosis fungoides was the most prevalent variant (49%). Most patients were treated with phototherapy (90%), with a response rate of 85%, and a complete response rate of 55% after the first course. There were no significant differences in response to phototherapy between the folliculotropic or other variants (p = 0.072). Similarly, delayed diagnosis, atopic diathesis, clonality, phototherapy type or number of treatments, were not associated with response to therapy, while protracted phototherapy was associated with prolonged remission. In conclusion, mycosis fungoides in the paediatric population is an indolent disease with a favourable prognosis and potentially prolonged response to phototherapy.

Identifiants

pubmed: 37449370
doi: 10.2340/actadv.v103.6557
pmc: PMC10391534
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

adv6557

Références

Pediatr Blood Cancer. 2016 Nov;63(11):1886-94
pubmed: 27229270
Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):361-4
pubmed: 9788416
J Pediatr Hematol Oncol. 2019 Jan;41(1):34-37
pubmed: 30130275
J Dtsch Dermatol Ges. 2007 Aug;5(8):662-8
pubmed: 17659039
Front Oncol. 2020 Jan 22;9:1558
pubmed: 32039026
Dermatol Clin. 2015 Oct;33(4):715-29
pubmed: 26433844
J Allergy Clin Immunol. 2017 Apr;139(4S):S65-S76
pubmed: 28390479
Blood. 2005 May 15;105(10):3768-85
pubmed: 15692063
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Arch Dermatol. 1984 Dec;120(12):1585-90
pubmed: 6508330
Acta Derm Venereol. 2003;83(6):451-6
pubmed: 14690342
J Am Acad Dermatol. 2014 Dec;71(6):1117-26
pubmed: 25264240
Clin Exp Dermatol. 2014 Jun;39(4):474-8
pubmed: 24825139
Pediatr Dermatol. 2010 Nov-Dec;27(6):607-13
pubmed: 21138468
Hematol Oncol Clin North Am. 2019 Feb;33(1):103-120
pubmed: 30497668
Clin Dermatol. 2019 May - Jun;37(3):255-267
pubmed: 31178107
J Dtsch Dermatol Ges. 2020 Dec;18(12):1379-1384
pubmed: 33029842
J Eur Acad Dermatol Venereol. 2013 Mar;27(3):295-300
pubmed: 22176010
J Am Acad Dermatol. 2014 Jun;70(6):993-1001
pubmed: 24629999
Pediatr Dermatol. 2020 Jan;37(1):18-28
pubmed: 31630432
J Am Acad Dermatol. 2003 Nov;49(5):873-8
pubmed: 14576667
Pediatr Dermatol. 2017 Sep;34(5):547-553
pubmed: 28804919
J Eur Acad Dermatol Venereol. 2022 May;36(5):671-679
pubmed: 35080278
J Am Acad Dermatol. 2016 Jan;74(1):27-58
pubmed: 26547257
JAMA Dermatol. 2021 Apr 1;157(4):431-438
pubmed: 33656521
Pediatr Blood Cancer. 2012 Feb;58(2):226-32
pubmed: 21445946
Blood. 2016 Jun 23;127(25):3142-53
pubmed: 27151889
Br J Dermatol. 2005 Sep;153(3):565-73
pubmed: 16120144
J Photochem Photobiol B. 1998 Jul 10;44(2):159-64
pubmed: 9757598
Australas J Dermatol. 2018 May;59(2):e143-e145
pubmed: 28731507

Auteurs

Orna Mirmovich Morvay (O)

Department of dermatology, Rambam Health Care Campus, Haifa, Israel. orna.mir@gmail.com.

Michal Ramon (M)

Department of dermatology, Rambam Health Care Campus, Haifa, Israel.

Ziad Khamaysi (Z)

Department of dermatology, Rambam Health Care Campus, Haifa, Israel.

Emily Avitan-Hersh (E)

Department of dermatology, Rambam Health Care Campus, Haifa, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH